Defining the intrahepatic immune response to hepatitis C virus
Defining the intrahepatic immune response to hepatitis C virus
批准号:
8250010
负责人:
Arash Grakoui
金额:
$35.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-04-01 至 2014-03-31
关键词:
Animal ModelAntigen PresentationAntigen-Presenting CellsAntiviral AgentsApoptosisAreaBiological AssayBiological ModelsCD4 Positive T LymphocytesCD8B1 geneCell CommunicationCell physiologyCellsCessation of lifeChronicCirrhosisDataDependenceDevelopmentDisease ProgressionEragrostisEventExperimental ModelsFailureFamilyFlow CytometryFunctional disorderFutureHepatic FibrogenesisHepatic Stellate CellHepatitis CHepatitis C virusHepatocyteHumanImmuneImmune responseImmunityIndividualInfectionInfectious hepatitidesInjury to LiverInvestigationKineticsKnockout MiceLiverLiver FibrosisLiver diseasesMediatingModelingMolecularMusOutcomePatientsPerisinusoidal SpacePhenotypePlayPopulationPositioning AttributePrimary carcinoma of the liver cellsProcessProductionProteinsPublishingRefractoryRegulatory T-LymphocyteRoleSamplingSignal TransductionSpecimenStagingStimulusT cell differentiationT cell responseT-LymphocyteTherapeuticTretinoinUnited StatesViralViral AntigensViral ProteinsVirusVirus DiseasesWorkchronic liver diseasecytokineexhaustin vitro Modelin vivoinhibitor/antagonistinterestintrahepaticliver transplantationnovelperipheral bloodprogramsprophylacticpublic health relevanceresponsesmall molecule
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Infection with hepatitis C virus (HCV) results in persistent liver disease in the majority of infected individuals and HCV-associated end-stage liver disease is now the leading indication for liver transplantation in the United States. Many studies have highlighted the importance of the T cell response for viral clearance and attributed persistent infection to an insufficient T cell response. However, in persistent HCV infection the factors leading to immune failure are not clear. We recently published work showing that the intrahepatic HCV-specific T cell response in chronically infected human patients does not mirror the response in the peripheral blood and that, in fact, phenotypically exhausted T cells characterize the liver infiltrating population. Accordingly, we postulate that in the natural course of HCV infection, viral persistence is a direct result of the inadequacy of the intrahepatic immune response and more specifically, that intrahepatic antigen presenting cells (APCs) modulate and impair the antiviral T cell response thereby contributing to viral persistence. Hepatic stellate cells (HSC) are a novel population of intrahepatic APC that undergo dramatic phenotypic and functional changes in response to liver injury or infection. This process is known to be important for liver fibrogenesis, but little is known of the importance of HSC as APCs and how APC function is changed during HCV infection. Our preliminary work indicates a transition from immunostimulatory to immunoinhibitory function upon activation of HSC. Thus, the work proposed here will focus on HSC and their ability to modulate T cell immunity through viral antigen presentation in the context of costimulatory or coinhibitory molecules and the influence that HCV has on this process. We will dissect the pair-wise relationships between HSC and T cells, HSC and HCV, while bringing together all three factors to determine the impact of this tripartite interaction on the outcome of HCV infection. We expect to find that HSC play a role in the intrahepatic T cell dysfunction during HCV infection and therefore promote persistent infection.
PUBLIC HEALTH RELEVANCE: Hepatitis C virus (HCV)-induced chronic liver disease with associated cirrhosis and hepatocellular carcinoma is now the leading indication for liver transplantation in the United States. There are currently an estimated 170 million HCV carriers worldwide and nearly 3 million in the U.S. (~2% of the population). We are seeking to elucidate and understand the mechanisms by which the host immune response fails in the majority of those infected and to future efforts to develop prophylactic and/or therapeutic HCV eradication strategies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Correlates of protective immunity to HCV and rational vaccine design
-
批准号:10393614
-
项目类别:
-
资助金额:$204.03万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Admin Core
-
批准号:10393615
-
项目类别:
-
资助金额:$40.81万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design
-
批准号:10205764
-
项目类别:
-
资助金额:$201.88万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Project 2
-
批准号:10205768
-
项目类别:
-
资助金额:$73.75万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Project 2
-
批准号:10393618
-
项目类别:
-
资助金额:$40.81万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Project 2
-
批准号:10608110
-
项目类别:
-
资助金额:$79.13万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design
-
批准号:10608105
-
项目类别:
-
资助金额:$205.42万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Admin Core
-
批准号:10205765
-
项目类别:
-
资助金额:$15.56万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Correlates of protective immunity to HCV and rational vaccine design: Admin Core
-
批准号:10608106
-
项目类别:
-
资助金额:$9.38万
-
财政年份:2021
-
负责人:Arash Grakoui
-
依托单位:
Dynamics of antigen specific B and Tfh responses during acute and chronic HCV
-
批准号:10063938
-
项目类别:
-
资助金额:$74.22万
-
财政年份:2017
-
负责人:Arash Grakoui
-
依托单位:
Dynamics of antigen specific B and Tfh responses during acute and chronic HCV
-
批准号:10305612
-
项目类别:
-
资助金额:$66.91万
-
财政年份:2017
-
负责人:Arash Grakoui
-
依托单位:
T cell compartmentalization and antiviral response
-
批准号:9127649
-
项目类别:
-
资助金额:$64.13万
-
财政年份:2016
-
负责人:Arash Grakoui
-
依托单位:
DEFINING THE INTRAHEPATIC IMMUNE RESPONSE TO HEPATITIS C VIRUS
-
批准号:8357563
-
项目类别:
-
资助金额:$3.29万
-
财政年份:2011
-
负责人:Arash Grakoui
-
依托单位:
MECHANISMS OF HEPATITIS C VIRUS PERSISTENCE
-
批准号:8357445
-
项目类别:
-
资助金额:$3.29万
-
财政年份:2011
-
负责人:Arash Grakoui
-
依托单位:
UNDERSTANDING MECHANISMS OF HCV PERSISTENCE
-
批准号:8172414
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
MECHANISMS OF HEPATITIS C VIRUS PERSISTENCE
-
批准号:8172391
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
Defining the intrahepatic immune response to hepatitis C virus
-
批准号:7781668
-
项目类别:
-
资助金额:$43.72万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
Defining the intrahepatic immune response to hepatitis C virus
-
批准号:8050079
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
Defining the intrahepatic immune response to hepatitis C virus
-
批准号:8460497
-
项目类别:
-
资助金额:$34.66万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
IMMUNOLOGICAL STRATEGIES FOR CURING CHRONIC HEPATITIS VIRUS INFECTIONS
-
批准号:8172415
-
项目类别:
-
资助金额:$4.39万
-
财政年份:2010
-
负责人:Arash Grakoui
-
依托单位:
海外基金